El
Eloxx Pharma
Waltham MAFounded 201340 employees
Private CapbiotechAcquiredRare Disease
Platform: Readthrough CF
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| ELO-7470 | ELO-7470 | Preclinical | 1 | CDK2 | MS | ||
| ELO-2344 | ELO-2344 | Phase 3 | 2 | PI3Kα | Prostate Ca | ||
| Doxasotorasib | ELO-8969 | Phase 1/2 | 2 | PD-L1 | SchizophreniaRett | ||
| ELO-7744 | ELO-7744 | Phase 2 | 2 | B7-H3 | CF |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (6)